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ABSTRACT: We recently reported on a controlled deactiva-
tion/detoxiﬁcation approach for obtaining cannabinoids with
improved druggability. Our design incorporates a metabolically
labile ester group at strategic positions within the THC struc-
ture. We have now synthesized a series of (−)-Δ8-THC ana-
logues encompassing a carboxyester group within the 3-alkyl
chain in an eﬀort to explore this novel cannabinergic chemo-
type for CB receptor binding aﬃnity, in vitro and in vivo
potency and eﬃcacy, as well as controlled deactivation by plasma esterases. We have also probed the chain’s polar characteristics
with regard to fast onset and short duration of action. Our lead molecule, namely 2-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-
hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic acid 3-cyano-propyl ester (AM7438), showed picomo-
lar aﬃnity for CB receptors and is deactivated by plasma esterases while the respective acid metabolite is inactive. In further in
vitro and in vivo experiments, the compound was found to be a remarkably potent and eﬃcacious CB1 receptor agonist with
relatively fast onset/oﬀset of action.
■ INTRODUCTION
(−)-Δ9-Tetrahydrocannabinol1 ((−)-Δ9-THC, 1, Figure 1)
and its congeners act at CB1 and CB2,2−4 two Gi/o-protein-
coupled cannabinoid receptors that are currently being targeted
for various conditions including pain, inﬂammation, neuro-
degeneration, glaucoma, eating and mental disorders, as well as
cancer.5−14 Owing to the undesirable side eﬀects associated
with CB1 receptor activation/deactivation as well as poor
pharmacokinetic/pharmacodynamic (PK/PD) properties, only
a limited number of cannabinergic drugs have been approved to
date.15 Thus, the development of safer THC-based medications
with favorable oral bioavailability, consistent eﬃcacy, and pre-
dictable time course of action and detoxiﬁcation remains to be
addressed.
Toward this end, we recently reported on a controlled
deactivation/detoxiﬁcation approach where the “soft” analogue/
drug concept of enzymatic deactivation was combined with a
“depot eﬀect” that is commonly observed with Δ9-THC and
other lipophilic cannabinoids. In our design, the compound’s
systemic half-life is determined by two factors. The ﬁrst reﬂects
the ability of the compound to sequester in some tissue reservoir
such as fatty tissue (depot eﬀect). The tissue sequestration aﬀects
the availability of the compound for receptor activation as well as
for hydrolytic deactivation through systemic circulation. This
process is dependent on the compound’s physicochemical pro-
perties and can be modulated by adjusting log P and PSA. Thus,
more lipophilic compounds are slowly released in the blood-
stream from the depot while more polar compounds are
expected to have less of a depot eﬀect. We have also conﬁrmed
that, in the compounds discussed here, the hydrolytic metabolic
pathway is the most dominant and is considerably faster than
other metabolic options such as reactions involving microsomal
enzymes. The second is the rate of enzymatic hydrolysis of a
metabolically labile ester group (−C(O)-O−) by blood esterases.
This can be calibrated by incorporating suitable stereochemical
features in the vicinity of the hydrolyzable moiety (enzymatic
eﬀect).16 Currently, we have developed two controlled-deactivation
cannabinergic templates based on the tricyclic classical canna-
binoid prototype. In the ﬁrst, the C-ring in THC was replaced
by a hydrolyzable seven-membered lactone,17 while in the
second, the metabolically labile ester group was placed at the
2′-position of the side chain pharmacophore (Figure 1).16
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In the present SAR study, we sought to probe the ester side
chain pharmacophore in the (−)-Δ8-THC prototype within a
novel series of analogues with regard to aﬃnity for the CB1 and
CB2 cannabinoid receptors, in vitro and in vivo potency and
eﬃcacy, as well as ability to control the half-lives of deactivation
through enzymatic action. An additional goal of this work was
to explore the polar characteristics of the side chain and gain
information related to the modulation of the depot eﬀect and
its role in the in vivo pharmacokinetic proﬁle of the analogues.
The above considerations led us to design ligands that retain
the metabolically labile group at the 2′-position of the side
chain and replace the ester group (−C(O)-O−) with the re-
verse ester (−O−C(O)−) as well as with the corresponding
thioester (−C(O)-S−) and the hydrolytically more stable
amide group (−C(O)-NH−) (Figure 2). To explore the chain
length, we synthesized analogues with four- to nine-atom-long
side chains. Additionally, to probe the ligand’s polarity, we
incorporated bromo-, cyano-, and imidazolyl-groups at the
distal side chain carbon atom. As with our previous work,16 to
regulate the rates of enzymatic inactivation while enhancing the
compound’s aﬃnities for CB receptors, we introduced benzylic
substituents contiguous to the metabolically vulnerable ester
group.
All novel compounds were characterized by determining
their in vitro CB1 and CB2 receptor aﬃnities. Of these, the
most interesting were assessed for their functional activities and
for their in vitro metabolic stabilities toward mouse plasma
esterases while a limited representative set of key compounds
was evaluated for their hypothermic and analgesic eﬀects in
vivo. Our data show that (−)-Δ8-THC analogues carrying
ﬁve- to nine-atom-long side chains that are substituted with
geminal dimethyl and cyclobutyl groups at the C1′-position
exhibit remarkably high aﬃnities for the CB1 and CB2 recep-
tors. As predicted, all novel analogues were found to be sus-
ceptible to enzymatic deactivation by plasma esterases in a
controllable manner, while their metabolites showed no or very
low cannabinergic activity. Additionally, all key compounds
were shown to be agonists for the CB1 receptor when tested
for their abilities to reduce cAMP levels and also produce the
characteristic CB1-mediated hypothermia and analgesia in rats
and mice. Equally important, in the hypothermia assay, the 6′-
cyano-2′-carboxy-Δ8-THC analogue 10a (AM7438) exhibited
10-fold higher potency as well as faster onset and shorter
duration of action than the less polar carboxy counterpart 2b.
Also, the oﬀset of the analgesic eﬀect was signiﬁcantly faster for
10a compared to 2b. Congruent with our rational design, these
in vivo results suggest that the depot eﬀect of our controlled
deactivation analogues can suitably be modulated by enhancing
the polar characteristics of the side chain pharmacophore
without any signiﬁcant loss of potency.
■ CHEMISTRY
Syntheses of the 4′-bromo- and 4′-cyano-butyl esters 6a−6c
and 7a−7c are summarized in Scheme 1. The required (−)-Δ8-
THC carboxylic acids 5a−5c were synthesized from commer-
cially available (3,5-dimethoxyphenyl)acetonitrile and (+)-cis/
trans-p-mentha-2,8-dien-1-ol in three to four steps following our
recently reported procedures.16 Alkylation of the respective
carboxylate anions with 1,4-dibromobutane under microwave
heating led to the corresponding esters 6a−6c in 45−63%
yields.16 Treatment of these bromides with sodium cyanide in
dimethyl sulfoxide18 produced the respective side chain cyano-
substituted analogues 7a−7c in 54−71% yields.
In a similar fashion, the tricyclic carboxylic acid 5b was
transformed to the side chain homologues 8a, 8b, and 9a−9d
in 47−87% yields (Scheme 2). Reaction of the 3-bromo-propyl
ester 9b with sodium cyanide or imidazole in the presence
of potassium carbonate, in dimethyl sulfoxide, led to the end
carbon substituted derivatives 10a and 10b (41−98% yields).
Synthesis of the reverse ester analogue 16 involves a Mits-
unobu esteriﬁcation reaction19 as the key step (Scheme 3).
Thus, reduction of nitrile 11 with diisobutylaluminum
hydride20 at −78 °C led to aldehyde 12 (92% yield), which
upon exposure to sodium borohydride in methanol21 aﬀorded
the respective alcohol 13 in excellent yield (94%). Cleavage of
the methyl ether groups in 13 using boron tribromide18 pro-
duced resorcinol 14 in 47% yield. Acid catalyzed condensation
of this intermediate with chiral terpenoid alcohol 17 in reﬂuxing
chloroform for 4−6 h gave (−)-Δ8-THC alcohol 15 in 21%
Figure 1. Design of the ﬁrst-generation side chain carboxylated (−)-Δ8-tetrahydrocannabinols with controllable deactivation and structures of the
prototype (−)-Δ9-THC and inactive metabolites.
Figure 2. Structure−activity relationship summary of the metabolically
vulnerable side chain pharmacophore in (−)-Δ8-tetrahydrocannabi-
nols.
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isolated yield along with unidentiﬁed byproducts. We were
able to improve this yield (28%) using microwave conditions
over a much shorter time period (10 min).16 Subsequently,
Mitsunobu esteriﬁcation of 15 with n-valeric acid using
triphenylphosphine and diethyl azodicarboxylate led to the
ﬁnal ester 16 (41% yield).
Treatment of the α,α-dimethyl-carboxylic acid 5b with
[bis(2-methoxyethyl)amino]sulfur triﬂuoride and coupling of
Scheme 1a
aReagents and conditions: (a) Br(CH2)4Br, NaHCO3, DMF, microwave irradiation, 165 °C, 12 min, 63% for 6a, 53% for 6b, and 45% for 6c; (b)
NaCN, DMSO, 50 °C, 12 h, 71% for 7a, 54% for 7b, and 63% for 7c.
Scheme 2a
aReagents and conditions: (a) RI, NaHCO3, DMF, microwave irradiation, 165 °C, 12 min, 64% for 8a and 87% for 8b; (b) RBr, NaHCO3, DMF,
microwave irradiation, 165 °C, 12 min, 48% for 9a, 51% for 9b, 47% for 9c, and 47% for 9d; (c) NaCN, DMSO, 50 °C, 12 h, 98% for 10a; (d)
imidazole, K2CO3, DMSO, rt, 14 h, 41% for 10b.
Scheme 3a
aReagents and conditions: (a) DIBAL-H, CH2Cl2, −78 °C, 1 h, 92%, (b) NaBH4, MeOH, rt, 1 h, 94%; (c) BBr3, CH2Cl2, −78 °C, 15 min then rt,
1 h, 47%; (d) (+)-cis/trans-p-mentha-2,8-dien-1-ol (17), p-TSA, CHCl3, microwave irradiation, 150 °C, 10 min, 28%; (e) DEAD, triphenylphosphine,
CH3(CH2)3COOH, THF, r , 20 h, 41%.
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the in situ generated acyl ﬂuoride22 with n-pentylamine aﬀorded
the (−)-Δ8-THC amide 18 in 70% yield (Scheme 4). Exposure
of the same starting material (5b) to the benzotriazole/thionyl
chloride reagent23 followed by treatment of the intermediate acyl
chloride 19 with n-propanethiol led to thioester 20 in 23% yield
for the two steps.
■ CANNABINOID RECEPTOR AFFINITIES
The abilities of compounds 6a−6c, 7a−7c, 8a, 8b, 9a−9d, 10a,
10b, 15, 16, 18, and 20 to displace the radiolabeled CB1/CB2
agonist CP-55,940 from membranes prepared from rat brain
(source of CB1) and HEK293 cells expressing either mouse
CB2 or human CB2 were determined as described earlier,18,20
and inhibition constant values (Ki) from the respective com-
petition binding curves are listed in Table 1 in which our
prototype (−)-Δ8-THC, as well as the ﬁrst-generation carboxy-
Δ8-THCs 2a−2c are included for comparison. The rat, mouse,
and human CB1 receptors have 97−99% sequence identity
across species and, as shown earlier,16 are not expected to
exhibit variations in their Ki values. However, mouse CB2
24
(mCB2) exhibits only 82% sequence identity with the human
clone3 (hCB2). This divergent nature of mCB2 and hCB2
receptors was shown in earlier work25,26 to be associated
with species-based diﬀerences in aﬃnity. For this reason, the
analogues were also tested on hCB2.
The compounds included in this study are (−)-Δ8-THC
analogues in which a four- to nine-atom-long side chain with or
without 1′-substituents incorporates an enzymatically vulner-
able group at the 2′- or 3′-positions. Optimization of the novel
carboxy or thiocarboxy-ester side chains was probed through
the synthesis of analogues carrying bromo-, cyano-, and
imidazolyl-substituents at the distal carbon atom. As predicted
based on our earlier results, the hydrolytic metabolites 5a−5c
and 15 have no signiﬁcant aﬃnities for CB1 and CB2 receptors,
thus minimizing the possibility of undesirable cannabinoid
receptor related side eﬀects. Comparison of the binding data of
(−)-Δ8-THC and its carboxyester congeners 2a, 6a, and 7a
suggests that extension of the linear chain from ﬁve to seven−
nine atoms, along with incorporation of an ester group at the
2′,3′-positions, enhances the binding aﬃnities of these
analogues for both the CB1 and CB2 receptors. We also
observed that incorporation of the bromo as well as the more
polar cyano substituents at the terminal carbon of the side
chain is well tolerated. Comparison of the binding data of our
prototype (−)-Δ8-THC and compound 8b demonstrates the
remarkable eﬀects of 1′,1′-dimethyl-2′-carboxyester substitution
(−C(CH3)2−C(O)O−) on the side chain pharmacophore.
Thus, 8b with the ﬁve-atom-long side chain exhibits 10-, 78-,
and 24-fold higher binding aﬃnities for rCB1, mCB2, and
hCB2 receptors, respectively, when compared to (−)-Δ8-THC.
The one-carbon shorter homologue 8a has signiﬁcantly
reduced aﬃnities for both CB receptors, indicating that a mini-
mum requirement for substantial aﬃnity for both receptors in
this series is a ﬁve-atom-long side chain. This high aﬃnity can
be maintained all through side chain lengths of nine atoms with
or without terminal bromine substituents (analogues 2b, 6b,
and 9a−c). Interestingly, this holds true when the terminal two
or three atoms of the chain are replaced by the polar cyano
group or the bulkier and amphiprotic imidazole ring (com-
pounds 10a, 10b and 7b). Notably, the cyano analogues 10a
and 7b exhibit remarkably high aﬃnities for the CB1 and CB2
receptors. However, extension of the ω-substituted imidazolyl
chain of 10b by one methylene group (compound 9d) results
in a reduction of the ligand’s aﬃnity for both cannabinoid
receptors, an eﬀect more accentuated in CB1 (∼8-fold reduction).
Taken together, these data suggest that the pharmacophoric limits
for an ω-substituted 1′,1′-dimethyl-2′-carboxyester chain could
not be extended beyond the nine atoms.
A comparison of the binding aﬃnities of the nonsubstituted
analogues 6a and 7a with their respective gem-dimethyl
counterparts 6b and 7b shows that introduction of two methyl
substituents at the 1′-position of an ω-substituted carboxylated
chain leads to an enhancement (20-fold maximum) in CB1 and
CB2 receptor aﬃnities. This increase in the ligand’s aﬃnities for
both CB1 and CB2 receptors holds true when the gem-dimethyl
substitution is modiﬁed to the bulkier cyclobutyl ring (ana-
logues 6c and 7c). An examination of the binding data of the
2′,3′-carboxyester analogue 2b and its sulfur and nitrogen
congeners 18 and 20 shows that the ester moiety (−C(O)-O−)
can be replaced by the respective thioester (−C(O)-S−) and
amide (−C(O)-NH−) groups. Likewise, analogue 16 incorpo-
rating the sterically less hindered retro ester group (−O−
C(O)−) at the 3′,4′-position maintains high aﬃnity for both
the CB1 and CB2 receptors.
In summary, the detailed SAR reported here shows that a
ﬁve- to nine-atom-long side chain with gem-dimethyl or
cyclobutyl substituents at the 1′-position and an enzymatically
vulnerable group within the 2′ or 3′ chain segment results in
analogues with remarkably high aﬃnities for both CB1 and
CB2 receptors. Importantly, addition of the bromo- or cyano-
groups as well as the bulky and amphiprotic imidazole ring at
the terminal carbon maintains or enhances the aﬃnity of the
ligand for the CB receptors.
Scheme 4a
aReagents and conditions: (a) (MeOCH2CH2)2NSF3, Et3N, CH3(CH2)4NH2, 0 °C, 15 min, then rt, 2 h, 70%; (b) SOCl2, 1H-benzotriazole,
CH2Cl2, rt, 20 min; (c) CH3(CH2)2SH, pyridine, CH2Cl2, rt, 3 h, 23%, two steps.
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Table 1. Aﬃnities (Ki) of Side Chain (−)-Δ8-THC Analogues for CB1 and CB2 Cannabinoid Receptors (±95% Conﬁdence
Limits) and Half-Lives (t1/2) of Representative Compounds for Mouse Plasma Esterases
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■ IN VITRO PLASMA STABILITY STUDIES
Representative analogues within this series were assessed for
their in vitro plasma stability toward mouse plasma esterases as
detailed in the Experimantal Section.16,17 It should be noted
that blood contains various esterases which play the major role
in the hydrolysis of compounds carrying ester, carbamate, or
phosphate bonds. These esterases include acetylcholinesterases
(ACHE), butyrylcholinesterases (BCHE), paraoxonases, and
carboxyesterases (in mice and rat but not in human plasma).
Esterase activity can be found mainly in plasma, with less
activity in red blood cells. Plasma albumin itself may also act as
an esterase under certain conditions. For example, albumin
contributes about 20% of the total hydrolysis of aspirin to
salicylic acid in human plasma. The esterase activity in blood
seems to be more extensive in small animals such as rats than in
large animals and humans.27 A comparison of the half-lives
(t1/2, Table 1) of the alkyl bromide and nitrile having no substi-
tution at the 1′-position (6a, 7a) with their 1′-gem-dimethyl
(6b, 7b) and 1′-cyclobutyl (6c, 7c) counterparts shows that the
plasma esterase stabilities of the analogues correlate well with
the presence and the size of 1′-substituents. Thus, the order of
metabolic stabilities for the bromo- and cyano-substituted
analogues is 6a < 7a < 6b < 7b < 6c < 7c, with the compounds
carrying the bulkier cyclobutyl group being the most hydro-
lytically stable. This trend with the ω-substituted eight- to nine-
atom-long side chain analogues parallels our earlier observa-
tions with the shorter (seven-atoms) and unsubstituted side chain
congeners 2a, 2b, and 2c.16 Another general observation through
this structure−stability relationship study is that regardless of the
1′-substituent, addition of a bromo- or cyano-group at the
terminal carbon of a seven-atom-long chain increases its stability
toward esterases with the cyano-substituted chain exhibiting the
highest stability (comparison of 2a with 6a and 7a, 2b with 6b
and 7b, and 2c with 6c and 7c).
The eﬀect of ω-substitution on the chain’s enzymatic stability
proﬁle was studied in more detail in the 1′-gem-dimethyl series
through the assessment of the half-lives of the cyano- and
imidazolyl-substituted analogues 10a, 10b, 7b, and 9d. We
observe that presence of a terminal cyano group or the larger
imidazole ring reduce the enzymatic lability of the 1′-gem-
dimethyl chain (analogue 2b) by 3- to 31-fold. As expected, the
sterically less hindered retro ester analogue 16 was more prone
to enzymatic hydrolysis when compared to the α,α-dimethyl-
carboxylated counterpart 2b, while the amide group (18) was
shown to have remarkable plasma stability. In agreement with
earlier work on the rates of hydrolysis of ethyl butyrate and
Table 1. continued
aAﬃnities for CB1 and CB2 were determined using rat brain (CB1) or membranes from HEK293 cells expressing mouse or human CB2 and
[3H]CP-55,940 as the radioligand following previously described procedures.18,20,51 Data were analyzed using nonlinear regression analysis. Ki values
were obtained from three independent experiments performed in triplicate and are expressed as the mean of the three values. bReported
previously.33 cReported previously.14 dHalf-lives (t1/2) for mouse plasma were determined as described under Experimental Section.
eNo observable
hydrolysis within 5 h. ND: not determined.
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ethyl thiobutyrate by pig liver esterases,28 the thioester 20
exhibits higher stability in mouse plasma esterases than the
respective oxoester 2b. Overall, our data show that the rate of
enzymatic inactivation of our side chain carboxyester Δ8-THCs
can be controlled by (1) structural features in the vicinity of the
hydrolyzable group and (2) substituents at the terminal carbon.
■ FUNCTIONAL CHARACTERIZATION
Functional characterization of key compounds for the rCB1
receptor was carried out by measuring the decrease in forskolin-
stimulated cAMP, as detailed earlier.16,18 Compounds were
initially screened in three diﬀerent concentrations (three-
point data), and the approximate EC50 values were calculated
(Table 2). Subsequently, the accurate EC50 value of the most
potent analogue 10a was determined from two independent
experiments (eight-point data) and listed in Table 2 along with
data for the related compounds 2b and 2c for comparison.
We observe that all tested analogues are full agonists at the
CB1 receptor while their EC50 values correlate well with their
respective binding aﬃnities. Of the compounds tested, the
carboxyester Δ8-THC analogues 2b and 2c as well as their
ω-substituted cyanide congener 10a were found to be the most
potent and eﬃcacious compounds within the series with EC50s
of 0.5, 0.4, and 0.9 nM, respectively.
■ MOLECULAR MODELING
As an aid in the interpretation of the data, we carried out con-
formational analyses and docking studies (detailed procedures
are given under Experimental Section) involving our lead
analogue 10a, the nonhydrolyzable counterpart (−)-Δ8-THC-
DMH as well as the parent compound (−)-Δ8-THC.
Conformational Analysis. Initial conformational analyses
of (−)-Δ8-THC, (−)-Δ8-THC-DMH, and 10a revealed a dif-
ference in the conformation of the side chains in their global
minimum energy conformers. Both (−)-Δ8-THC-DMH and
10a have their side chains oriented orthogonal to the phenol
ring, while for (−)-Δ8-THC, the ﬁve-carbon side chain extends
in the same plane as its phenol ring. Initial in vacuo confor-
mational analyses of 10a identiﬁed an intramolecular hydrogen
bond between the cyano nitrogen and the phenolic hydroxyl.
The 10a phenolic hydroxyl to cyano nitrogen hydrogen bond
heteroatom distance (N−O) and hydrogen bond (O−H− −N)
angle were 3.22 Å and 144°, respectively. The intramolecular
hydrogen bond in 10a was not found in the global minimum
energy conformation from a second conformational search
performed using the OPSL2005 force ﬁeld with an implicit
GB/SA solvent model for water. Preliminary results from a
70 ns NAMD molecular dynamics simulation of 10a in a fully
hydrated POPC lipid bilayer found a very low incidence of
this internal hydrogen bond as well (unpublished data). For
this reason, the nearest low energy conformer without an
intramolecular hydrogen bond (which was 1.77 kcal/mol above
the initial global min) was used for the calculation of confor-
mational energy costs for 10a. The ﬁrst and second side chain
dihedrals of this conformer compare well with the global
minimum energy conformer of (−)-Δ8-THC-DMH, shown in
Table 3. Finally, the phenolic hydroxyls of all three ligands were
found to prefer the proton directed toward the C2 phenyl ring
position nearer the side chain and with the value of the C2−
C1−O1−H1 dihedral near zero. A comparison of the lowest
energy conformation of 10a without the internal hydrogen
bond to those of (−)-Δ8-THC-DMH and (−)-Δ8-THC is
shown in Figure 3.
Docking Studies. To provide a representation for the inter-
action of the above three compounds with the hCB1 receptor,
we carried out docking studies with an activated form of a CB1
receptor model and calculated relative ligand/receptor
interaction energies. Glide docking studies of 10a in the
activated CB1 receptor revealed a signiﬁcant role for the ester
group at the 2′ position. The carbonyl oxygen within the ester
group has a hydrogen bonding interaction with T3.33(197) as
shown in Figure 4A. The hydrogen bond heteroatom distance
(O−O) and hydrogen bond (O−H− −O) angle are 2.56 Å and
165°, respectively. The T3.33(197) hydrogen bonding
interaction is not available to the (−)-Δ8-THC-DMH counter-
part or the parent compound (−)-Δ8-THC as shown in parts B
and C of Figure 4. However, all three compounds modeled in
the Glide docking studies have a phenolic hydroxyl that
interacts directly with K3.28(192). The K3.28(192) and 10a
phenolic hydroxyl hydrogen bond heteroatom distance (N−O)
and hydrogen bond (N−H− −O) angle are 2.73 Å and 170°,
respectively. The K3.28(192) and (−)-Δ8-THC-DMH phe-
nolic hydroxyl hydrogen bond heteroatom distance (N−O)
and hydrogen bond (N−H− −O) angle are 2.69 Å and 171°,
respectively. Finally, the K3.28(192) and (−)-Δ8-THC phenolic
hydroxyl hydrogen bond heteroatom distance (N−O) and
hydrogen bond (N−H− −O) angle are 2.64 Å and 168°,
respectively.
Glide XP scores adjusted for ligand strain reﬂect the rank
order of Kis (Table 3) in rCB1 with (10a = −5.7 kcal/mol) ≈
((−)-Δ8-THC-DMH = −5.4 kcal/mol) < ((−)-Δ8-THC =
−4.1 kcal/mol). For a list of Glide XP scores in rank order and
adjusted by ligand conformational cost, see Supporting
Information, Tables S2−S4. A breakdown of ligand/receptor
interaction energies revealed the importance of van der Waals
interactions for each of ligands and how the two 1′,1′-dimethyl
analogues (10a and (−)-Δ8-THC-DMH) have far more of
these interactions than (−)-Δ8-THC. The (−)-Δ8-THC-DMH
and 10a have nine and eight van der Waals interactions better
Table 2. Functional Potencies (EC50) of Selected (−)-Δ8-
THC Ester Analogues for the rCB1 Cannabinoid Receptor
rCB1 (EC50, nM)
a
compd 3-pointsb 8-pointsc E(max) (%)
d
7a 10−100
2b <1 0.5 (0.1−1.2)e 92e
8b 1−10




2c <1 0.4 (0.2−1.2)e 90e
7c 1−10
aFunctional potencies at rCB1 receptor were determined by mea-
suring the decrease in forskolin-stimulated cAMP levels, as described
in Experimental Section.16,18 bThree point data were obtained from
one experiment (3 points) run in duplicate (less accurate EC50 values).
cData are average of two independent experiments (8 points) run in
triplicate, and 95% conﬁdence intervals for the EC50 values are given in
parentheses. EC50 values were calculated using nonlinear regression
analysis. dForskolin stimulated cAMP levels were normalized to 100%
and E(max) is the maximum inhibition of forskolin stimulated cAMP
levels and is presented as the percentage of CP-55,940 response at
500 nM. eReported previously.16
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than −2.0 kcal/mol, respectively, while (−)-Δ8-THC has
ﬁve such interactions. The most important van der Waals
interactions in common for the 1′,1′-dimethyl analogues are
F3.25(189), L3.29(193), F(268), M6.55(363), M(371),
S7.39(383), and C7.42(386). The (−)-Δ8-THC parent interacts
in a likewise manner with only F3.25(189), L3.29(193), F(268),
M(371), and S7.39(383). Of these residues, L3.29(193), F(268),
M6.55(363), and M(371) form part of a tunnel-shaped
hydrophobic enclosure between TMHs 3 and 6 for the side
chain of each analogue to occupy. Unique to 10a is the van der
Waals interaction with V3.32(196), and unique to (−)-Δ8-THC-
DMH is F7.35(329). A full listing of all ligand/receptor interac-
tion energies is given in the Supporting Information, Tables 5−7.
Total ligand/receptor interaction energies also follow the
trend of the Glide XP scores and Kis in rCB1 with (10a =
−42.9 kcal/mol) ≈ ((−)-Δ8-THC-DMH = −44.4 kcal/mol) <
((−)-Δ8-THC = −35.6 kcal/mol). The docked conformational
cost for each ligand after the post Glide minimization (10a,
0.18 kcal/mol; (−)-Δ8-THC-DMH, 0.28 kcal/mol; and
(−)-Δ8-THC, 0.13 kcal/mol) was small. Compound 10a did
not have a statistically signiﬁcant lower Ki compared to (−)-Δ8-
THC-DMH, even though Glide docking studies identiﬁed two
hydrogen bonds for 10a compared to one hydrogen bond for
(−)-Δ8-THC-DMH. This may be due to the energetic cost for
10a to place its hydrophilic ester and cyano moieties in a
generally hydrophobic pocket in the CB1 receptor. This cost
likely causes the two Kis to be essentially equivalent.
■ IN VIVO BEHAVIORAL CHARACTERIZATION
Representative analogues within this series were initially screened
using the hypothermia test in rats (data not shown), and the
order of the potency was found to be 10a > 7b ≥ 6b > 2b ≈
20 ≥ 16 ≈ 8b ≥ 18. Subsequently, the most promising compound
10a was studied in more detail and its in vivo hypothermic and
antinociceptive proﬁles were compared to those of the earlier
analogue 2b as well as with the nonhydrolyzable parent com-
pound (−)-Δ8-THC-DMH.
Hypothermia Testing. Body temperature was measured in
isolated rats over a 6 h period following drug injection (detailed
procedures are given in the Experimental Section). Compound
10a decreased core body temperature in a dose-dependent
manner, with a dose of 0.1 mg/kg reducing body temperature
up to 4.5 ± 0.5 °C from an average baseline of 37.8 ± 0.1 °C
(Figure 5). Its ED50 value (i.e., the dose required to reduce tem-
perature by 3 °C) was 0.034 mg/kg (95% CI: 0.026, 0.041 mg/kg).
For comparison, the eﬀects of our ﬁrst-generation analogue 2b
Table 3. Comparison of Side Chain Dihedral Values for Global Minimum Energy Conformers and Binding Aﬃnities (Ki) of Key
Analogues
Ki = 0.5 nM (rCB1),
= 0.8 nM (mCB2) (deg) Ki = 0.9 nM (rCB1), = 1.4 nM (mCB2) (deg) Ki = 47.6 nM (rCB1), = 39.3 nM (mCB2) (deg)
side chain dihedral 10a no int H-bond 10a (−)-Δ8-THC-DMH (−)-Δ8-THC
C2−C3−C1′−C2′ −38.3 −54.5 −52.3 −85.6
C3−C1′−C2′−(C3′, O3′) −60.2 −68.7 −60.0 179.9
C1′−C2′−(C3′, O3′)−C4′ 174.6 176.1 175.2 −179.9
C2′−(C3′, O3′)−C4′−C5′ −164.7 −174.5 179.5 180.0
(C3′, O3′)−C4′−C5′−C6′ 54.4 61.4 179.1
C4′−C5′−C6′−C7′ 54.3 179.1 180.0
Figure 3. 10a is the lowest energy conformer that does not have the
internal H-bond and is shown on the left. The (−)-Δ8-THC-DMH
global minimum energy conformer is in the middle and (−)-Δ8-THC
is on the right. All carbons atoms are shown in cyan.
Figure 4. (A−C) (Left Panel, A−C) Extracellular viewpoint of each
ligand/receptor complex. Termini and loops are not shown in this
panel. Ligand carbons are colored cyan and hydrophilic interactions
are displayed with amino acid carbons in violet. (Right Panel, A−C)
Side view of ligand/receptor complexes as if looking through TMH1, 2
(not displayed). Hydrophobic interacting residues with better than
−2.0 kcal/mol ligand interaction energies are displayed with brown
carbons. Hydrophilic ligand interactions are displayed with the amino
acid carbons in violet.
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and those of the (−)-Δ8-THC-DMH are also shown. The ED50
values were 0.37 (0.14, 0.73 with 95% CI) for 2b and 0.29
(0.18, 0.45 with 95% CI) for (−)-Δ8-THC-DMH. Thus, 10a is
approximately 8−10-fold more potent than (−)-Δ8-THC-DMH
and 2b. Limited extended studies comparing hypothermia induced
by equipotent doses of the 6′-cyano-2′-carboxy-Δ8-THC analogue
10a and its structurally related analogues 2b and (−)-Δ8-THC-
DMH for 12 h provided an estimate of their in vivo times of
action. Thus, at a dose of 0.03 mg/kg, near its ED50 value,
compound 10a reduced body temperature by 2 °C within 3 h
of injection and these eﬀects were not observed 6 h after
injection (see Supporting Information, Figure S1). This was
compared with the eﬀects of equivalent doses (near their ED50
values) of 2b and (−)-Δ8-THC-DMH. Thus, for 2b, a dose of
0.3 mg/kg produced eﬀects that persisted for at least 6 h after
injection while a dose of 0.3 mg/kg of (−)-Δ8-THC-DMH
produced an equivalent reduction in temperature beyond 12 h
after injection. It should be noted that in order to compare
equiactive doses of the most potent compound 10a with those
of the in vivo less potent (−)-Δ8-THC-DMH and 2b, we have
used diﬀerent doses of the three drugs that are consistent with
their ED50 values. Our data indicate that the depot eﬀect as
reﬂected in the log P and PSA values (Table 4) plays the most
dominant role in determining the in vivo hypothermic half-lives
of compounds 10a, 2b, and the nonhydrolyzable (−)-Δ8-THC-
DMH. Thus, notwithstanding the shorter in vitro hydrolytic
half-life of compound 2b, when compared to 10a, this
compound has a longer in vivo half-life. These results are
represented in Table 4.
Analgesia Testing. The pharmacokinetic proﬁles of ana-
logues bearing the carboxyester (2b) and the more polar cyano-
carboxyester (10a) side chains were further studied in the CB1
receptor-characteristic analgesia test in mice, and the results are
depicted in Figure 6 (the dose response graph for four doses of
10a are given under Supporting Information, Figure S2). A
mixed model repeated measures ANOVA (IBM software
package SPSS, v.21) applied to the tail-ﬂick latency data pro-
duced by compounds 10a and 2b during the descending phase
(180 and 360 min) showed signiﬁcant main eﬀects for drug
(D) (F1.44 = 8.98; p ≤ 0.004), dose-level (L) (F1.44 = 40.95; p ≤
0.001), and time (T) (F1.44 = 28.46; p ≤ 0.001). Of more
interest, however, is that pairwise comparisons within these
parameters (D, L, and T) using Sidak multiple comparison
t test procedure suggested signiﬁcant diﬀerences for all three
parameters (p = 0.05). Thus, the tail-ﬂick latencies were dose-
and time-dependent for both compounds in a similar manner,
and because the pairwise comparison for drug was also
signiﬁcant, the oﬀset of the analgesia eﬀect was signiﬁcantly
faster for 10a compared to 2b. The average (±SEM) baseline
tail-ﬂick withdrawal latency for all mice (N = 24) examined
with compound 10a was 0.99 ± 0.05 s.
Overall, our in vivo experiments show that in rats, compound
10a is approximately a 10−30-fold more potent as a canna-
binoid agonist when compared to 2b and (−)-Δ8-THC-DMH.
Also, this more potent analogue has a faster onset and shorter
duration of action when compared to the less polar counterpart
2b and the lipophilic and nonhydrolizable parent compound
(−)-Δ8-THC-DMH. Our antinociception data in mice clearly
show that the cyano-carboxyl-analogue 10a has a shorter
duration of action than its congener with no cyano substitution
(2b).
■ CONCLUSIONS
In summary, as a continuation of our earlier work on the
controlled deactivation/detoxiﬁcation ligand development
project, we sought to probe the novel carboxyester side chain
Figure 5. Eﬀects of 10a, 2b, and Δ8-THC-DMH or vehicle (above V)
on body temperature. Symbols represent the group mean ± SEM (n =
6 rats). Abscissa, dose in mg/kg; ordinate, change in body temperature
from an average baseline of 37.8 ± 0.1 °C. Data with compound 2b
and Δ8-THC-DMH published previously.16
Table 4. Calculated log P and tPSA Values for (−)-Δ8-THC-
DMH, 2b, and 10a, and Duration of Their Hypothermic
Eﬀects in Rats
compd clogPa tPSAa
duration of hypothermic eﬀects in
ratsb
(−)-Δ8-THC-DMH 9.1 29.5 t > 12 h
2b 6.6 55.8 t = 6−12 h
10a 5.0 79.5 t < 6 h
aCalculations were performed using ChemBioDraw Ultra 14.0 software.
bHypothermic eﬀects were determined using equiactive doses of the
test compounds.
Figure 6. Tail-ﬂick latencies in a hot water bath (52 °C) after
administration of 0.3 and 1.0 mg/kg of compounds 10a and 2b at four
time-points (20, 60, 180, and 360 min postadministration) using male
CD-1 mice. Abscissa, time (min) after injection; ordinate, tail-ﬂick
withdrawal latencies expressed as a percentage of maximum possible
eﬀect (% MPE; group mean ± SEM). Data for compound 2b are
reproduced from our earlier work.16
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pharmacophore in (−)-Δ8-THCs for CB receptor binding
aﬃnity, in vitro and in vivo potency and eﬃcacy, as well as its
eﬀects on the half-lives of deactivation through enzymatic
activity. We have also explored the chain’s polar characteristics
that are associated with the depot eﬀect, in an eﬀort to produce
cannabinoids with faster onset/oﬀset and shorter duration of
action than the currently existing (−)-Δ8-THC analogues. In
connection with our earlier work where we focused on the
chain’s benzylic position and the related subsite within the
receptor’s binding domain,18,20,29−33 the current SAR study
extends the mapping of the chain’s pharmacophoric space
beyond the 1′-carbon and argues that both CB receptors can
tolerate polar groups and atoms within the second and the
fourth position of the chain. We are hopeful that these obser-
vations will provide us with new opportunities for the design of
high aﬃnity/eﬃcacy novel analogues with improved selectiv-
ities for the two cannabinoid receptors. The most successful
compound identiﬁed through this careful study, namely
2-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic acid 3-cyano-
propyl ester (10a), is a remarkably potent and eﬃcacious CB1
receptor agonist with relatively shorter duration of action than its
less polar 2′-carboxy-(−)-Δ8-THC-DMH counterpart and the
highly lipophilic and long lasting (−)-Δ8-THC-DMH. Our data
support the hypothesis that the pharmacological half-lives of our
selectively detoxiﬁed analogues can be controlled by the joint
modulation of their relative stabilities for plasma esterases as well
as through variation of their polar characteristics and thus to the
depot eﬀects.
■ EXPERIMENTAL SECTION
Materials. All reagents and solvents were purchased from Aldrich
Chemical Co., unless otherwise speciﬁed, and used without further
puriﬁcation. All anhydrous reactions were performed under a static
argon atmosphere in ﬂame-dried glassware using scrupulously dry
solvents. Flash column chromatography employed silica gel 60 (230−
400 mesh). All compounds were demonstrated to be homogeneous by
analytical TLC on precoated silica gel TLC plates (Merck, 60 F245 on
glass, layer thickness 250 μm), and chromatograms were visualized by
phosphomolybdic acid staining. Melting points were determined on a
micromelting point apparatus and are uncorrected. IR spectra were
recorded on a PerkinElmer Spectrum One FT-IR spectrometer. NMR
spectra were recorded in CDCl3, unless otherwise stated, on a Bruker
Ultra Shield 400 WB plus (1H at 400 MHz, 13C at 100 MHz) or on a
Varian INOVA-500 (1H at 500 MHz, 13C at 125 MHz) spectrometers,
and chemical shifts are reported in units of δ relative to internal TMS.
Multiplicities are indicated as br (broadened), s (singlet), d (doublet),
t (triplet), q (quartet), and m (multiplet), and coupling constants (J)
are reported in hertz (Hz). Low and high-resolution mass spectra were
performed in School of Chemical Sciences, University of Illinois at
Urbana−Champaign. Mass spectral data are reported in the form of
m/z (intensity relative to base = 100). Elemental analyses were obtained
in Baron Consulting Co, Milford, CT, and were within ±0.4% of the
theoretical values (see Supporting Information). Purities of the tested
compounds were determined by elemental analysis or by HPLC (using
Waters Alliance HPLC system, 4.6 mm × 250 mm, Supelco Discovery
column, acetonitrile/water with 8.5% o-phosphoric acid) or by LC/MS
analysis using a Waters MicroMass ZQ system (electrospray ionization
(ESI) with Waters-2525 binary gradient module coupled to a
photodiode array detector (Waters-2996) and ELS detector (Waters-
2424) using a XTerra MS C18 (5 μm, 4.6 mm × 50 mm column and
acetonitrile/water) and were >95%.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]acetic Acid 4-Bromo-butyl Ester (6a). A
stirred mixture of 5a (175 mg, 0.58 mmol), dibromobutane (313 mg,
1.45 mmol), and sodium bicarbonate (73 mg, 0.87 mmol) in DMF
(2 mL) was heated at 165 °C for 12 min using microwave irradiation.
The reaction mixture was cooled to room temperature and diluted
with water and ethyl acetate. The organic layer was separated, and the
aqueous phase was extracted with ethyl acetate. The combined organic
layer was washed with brine, dried (MgSO4), and concentrated under
reduced pressure. Puriﬁcation by ﬂash column chromatography on
silica gel gave 6a (159 mg, 63% yield) as a light-yellow gum. IR
(CHCl3): 3407, 2967, 2928, 1712 (s, >CO), 1621, 1583, 1431,
1254 cm−1. 1H NMR (500 MHz, CDCl3) δ 6.33 (d, J = 1.0 Hz, 1H,
4-H), 6.24 (d, J = 1.0 Hz, 1H, 2-H), 5.42 (m as d, J = 4.0 Hz, 1H, 8-
H), 5.23 (s, 1H, OH), 4.12 (t, J = 6.5 Hz, 2H, −OCH2−), 3.45 (s, 2H,
−CH2−C(O)O−), 3.39 (t, J = 6.5 Hz, 2H, −CH2Br), 3.19 (dd, J =
15.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.69 (td, J = 11.0 Hz, J = 4.5 Hz, 1H,
10a-H), 2.19−2.10 (m, 1H, 7α-H), 1.94−1.76 (m, 7H, 10β-H, 7β-H,
6a-H, −CH2-CH2-CH2-Br, −CH2-CH2-CH2-Br), 1.69 (s, 3H, 9-CH3),
1.37 (s, 3H, 6β-CH3), 1.09 (s, 3H, 6α-CH3). Mass spectrum (EI) m/z
(relative intensity) 438 (M++ 2, 97), 436 (M+, 97), 395 (38), 393
(38), 355 (95), 353 (95), 330 (60), 316 (38), 287 (46), 273 (48), 257
(45), 247 (98), 233 (60), 213 (100).Exact mass (EI) calculated for
C22H29O4Br (M
+), 436.1249; found, 436.1252. HPLC (4.6 mm × 250 mm,
Supelco discovery column, acetonitrile/water) showed purity 97.5% and
retention time 12.6 min for the title compound. LC/MS analysis (Waters




butyl Ester (6b). The synthesis was carried out as described for 6a
using 5b (200 mg, 0.61 mmol), dibromobutane (330 mg, 1.53 mmol),
and sodium bicarbonate (77 mg, 0.92 mmol) in DMF and gave 6b
(148 mg, 53% yield) as a light-yellow gum. IR (neat): 3403, 2970,
2917, 1727, and 1703 (s, >CO), 1620, 1577, 1416, 1256 cm−1. 1H
NMR (500 MHz, CDCl3) δ 6.41 (d, J = 2.0 Hz, 1H, 4-H), 6.25 (d, J =
2.0 Hz, 1H, 2-H), 5.42 (m as d, J = 5.0 Hz, 1H, 8-H), 5.18 (s, 1H,
OH), 4.09 (t, J = 6.5 Hz, 2H, −OCH2−), 3.32 (t, J = 6.5 Hz, 2H,
−CH2Br), 3.19 (dd, J = 15.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.69 (td, J =
11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.18−2.10 (m, 1H, 7α-H), 1.85−1.68
(m and s overlapping, 10H, 10β-H, 7β-H, 6a-H, −CH2−CH2− of the
side chain and 9-CH3, especially 1.70 s, 9-CH3), 1.51 (s, 6H,
−C(CH3)2−), 1.38 (s, 3H, 6β-CH3), 1.10 (s, 3H, 6α-CH3). 13C NMR
(125 MHz, CDCl3) δ 177.8 (>CO), 155.7 (C-1 or C-5), 155.1 (C-5
or C-1), 144.0, 134.9, 119.4, 112.0, 107.1, 105.3, 77.0 (C-6), 64.3
(−OCH2−), 46.3, 45.0, 35.9, 33.3, 31.7, 29.3, 28.0, 27.7, 27.2, 26.2,
26.2, 23.8, 18.7. Mass spectrum (ESI) m/z (relative intensity) 467
(M++ 2 + H, 100), 465 (M+ + H, 100), 285 (30). Exact mass (ESI)
calculated for C24H34O4Br (M
+ + H), 465.1640; found, 465.1647.
LC/MS analysis (Waters MicroMass ZQ system) showed purity




butyl Ester (6c). The synthesis was carried out as described for 6a
using 5c (145.0 mg, 0.42 mmol), dibromobutane (136 mg, 0.63 mmol),
and sodium bicarbonate (39 mg, 0.46 mmol) in DMF and gave 6c
(90 mg, 45% yield) as a light-yellow gum. IR (neat): 3407, 2968, 2915,
1728, and 1705 (s, >CO), 1622, 1416, 1258 cm−1. 1H NMR
(500 MHz, CDCl3) δ 6.39 (d, J = 2.0 Hz, 1H, 4-H), 6.24 (d, J = 2.0 Hz,
1H, 2-H), 5.85 (s, 1H, −OH), 5.42 (m as d, J = 4.5 Hz, 1H, 8-H), 4.10
(m, 2H, −OCH2−), 3.31 (t, J = 6.5 Hz, 2H, −CH2Br), 3.24 (dd, J =
16.0 Hz, J = 4.0 Hz, 1H, 10α-H), 2.79−2.66 (m, 3H, 10a-H, 2H of the
cyclobutane ring, overlapping), 2.46 (m as qt, J = 9.0 Hz, 2H of the
cyclobutane ring), 2.19−2.10 (m, 1H, 7α-H), 1.99−1.90 (m, 1H of the
cyclobutane ring), 1.89−1.64 (m and s overlapping, 11H, 10β-H, 7β-H,
6a-H, 1H of the cyclobutane ring, −CH2CH2CH2Br, 9-CH3, especially
1.69 s, 9-CH3), 1.38 (s, 3H, 6β-CH3), 1.09 (s, 3H, 6α-CH3). Mass
spectrum (ESI) m/z (relative intensity) 501 (M+ + 2 + Na, 33), 499
(M+ + Na, 33), 479 (M+ + 2 + H, 100), 477 (M+ + H, 100), 297 (30).
Exact mass (ESI) calculated for C25H34O4Br (M
+ + H), 477.1640;
found, 477.1636. LC/MS analysis (Waters MicroMass ZQ system)
showed purity 97% and retention time 5.6 min for the title compound.
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2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]acetic Acid 4-Cyano-butyl Ester (7a). A
solution of bromide 6a (80 mg, 0.18 mmol) and sodium cyanide
(88 mg, 1.8 mmol) in anhydrous DMSO (5 mL) was stirred at 50 °C
for 3 h under argon. The reaction mixture was cooled to room tem-
perature and diluted with water and ethyl acetate. The organic layer
was separated, and the aqueous layer was extracted with ethyl acetate.
The combined organic layer was washed with brine, dried (MgSO4),
and evaporated under reduced pressure. Puriﬁcation by ﬂash column
chromatography on silica gel (20% ethyl acetate in hexane) aﬀorded 7a
(50 mg, 71% yield) as a light-yellow gum. IR (neat): 3405, 2926, 2249
(CN), 1732 (s, >CO), 1621, 1583, 1431, 1262, 1182 cm−1. 1H
NMR (500 MHz, CDCl3) δ 6.31 (d, J = 2.0 Hz, 1H, 4-H), 6.27 (d, J =
2.0 Hz, 1H, 2-H), 5.72 (s, 1H, OH), 5.42 (m as d, J = 4.0 Hz, 1H, 8-
H), 4.14 (t, J = 6.0 Hz, 2H, −OCH2−), 3.46 (s, 2H, −CH2−
C(O)O−), 3.22 (dd, J = 15.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.69 (td, J =
11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.35 (t, J = 7.0 Hz, 2H, −CH2CN),
2.17−2.09 (m, 1H, 7α-H), 1.85−1.70 (m, 7H, 10β-H, 7β-H, 6a-H,
−CH2−CH2− of the side chain), 1.68 (s, 3H, 9-CH3), 1.37 (s, 3H, 6β-
CH3), 1.09 (s, 3H, 6α-CH3). Mass spectrum (EI) m/z (relative
intensity) 383 (M+, 32), 368 (10), 340 (12), 315 (8), 300 (40), 279
(13), 213 (38), 205 (29), 97 (38), 83 (41), 69 (71), 57 (100). Exact
mass (EI) calculated for C23H29O4N (M
+), 383.2097; found, 383.2092.
LC/MS analysis (Waters MicroMass ZQ system) showed purity 96.5%
and retention time 6.8 min for the title compound.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic Acid 4-Cyano-
butyl Ester (7b). The synthesis was carried out as described for 7a
using 6b (20 mg, 0.04 mmol) and sodium cyanide (21 mg, 0.43 mmol)
in anhydrous DMSO and gave 7b (9.5 mg, 54% yield) as light-yellow
gum. IR (CHCl3): 3405, 2973, 2249 (CN), 1727 and 1705 (s, >CO),
1620, 1578, 1417, 1258, 1184 cm−1. 1H NMR (500 MHz, CDCl3) δ
6.41 (d, J = 2.0 Hz, 1H, 4-H), 6.26 (d, J = 2.0 Hz, 1H, 2-H), 5.42 (m as
d, J = 5.0 Hz, 1H, 8-H), 5.26 (s, 1H, OH), 4.11 (t, J = 6.5 Hz, 2H,
−OCH2−), 3.20 (dd, J = 15.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.69 (td, J =
11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.28 (t, J = 6.5 Hz, 2H, −CH2CN),
2.18−2.10 (m, 1H, 7α-H), 1.87−1.72 (m, 5H, 10β-H, 7β-H, 6a-H,
−CH2− of the side chain), 1.70 (s, 3H, 9-CH3), 1.68−1.58 (m, 2H,
−CH2− of the side chain), 1.51 (s, 3H, −C(CH3)2−), 1.50 (s, 3H,
−C(CH3)2−), 1.38 (s, 3H, 6β-CH3), 1.10 (s, 3H, 6α-CH3). Mass
spectrum (ESI) m/z (relative intensity) 434 (M+ + Na, 10), 412
(M+ + H, 100), 285 (5). Exact mass (ESI) calculated for C25H34NO4
(M+ + H), 412.2488; found, 412.2480. LC/MS analysis (Waters
MicroMass ZQ system) showed purity 98% and retention time 6.8 min
for the title compound.
1-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]- cyclobutanecarboxylic Acid 4-Cyano-
butyl Ester (7c). The synthesis was carried out as described for 7a
using 6c (180 mg, 0.38 mmol) and sodium cyanide (186 mg, 3.8 mmol)
in anhydrous DMSO and gave 7c (100 mg, 63% yield) as light-yellow
gum. IR (CHCl3): 3400, 2970, 2250 (CN), 1723 and 1703 (s, >CO),
1619, 1577, 1417, 1268, 1183 cm−1. 1H NMR (500 MHz, CDCl3) δ
6.37 (d, J = 1.5 Hz, 1H, 4-H), 6.26 (d, J = 1.5 Hz, 1H, 2-H), 5.95 (s, 1H,
−OH), 5.42 (m as d, J = 4.0 Hz, 1H, 8-H), 4.11 (t, J = 5.5 Hz, 2H,
−OCH2−), 3.26 (dd, J = 16.5 Hz, J = 5.0 Hz, 1H, 10α-H), 2.79−2.67
(m, 3H, 10a-H, 2H of the cyclobutane ring, overlapping), 2.46 (m, 2H
of the cyclobutane ring), 2.26 (t, J = 7.0 Hz, 2H, −CH2CN), 2.18−2.10
(m, 1H, 7α-H), 2.00−1.90 (m, 1H of the cyclobutane ring), 1.89−1.71
(m, 6H, 10β-H, 7β-H, 6a-H, 1H of the cyclobutane ring, −CH2− of the
side chain), 1.69 (s, 3H, 9-CH3), 1.63−1.54 (m, 2H, −CH2− of the side
chain), 1.38 (s, 3H, 6β-CH3), 1.09 (s, 3H, 6α-CH3). Mass spectrum
(ESI) m/z (relative intensity) 446 (M+ + Na, 50), 424 (M+ + H, 100),
297 (5). Exact mass (ESI) calculated for C26H34NO4 (M
+ + H),
424.2488; found, 424.2491. LC/MS analysis (Waters MicroMass ZQ
system) showed purity 98% and retention time 4.9 min for the title
compound. Anal. (C26H33NO4) C, H.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic Acid Methyl Ester
(8a). The synthesis was carried out as described for 6a using 5b
(240 mg, 0.73 mmol), iodomethane (260 mg, 1.83 mmol), and sodium
bicarbonate (92 mg, 1.09 mmol) in DMF and gave 8a (160 mg, 64%
yield) as a light-yellow gum. IR (neat): 3412, 2962, 2932, 1728, and
1702 (s, >CO), cm−1. 1H NMR (500 MHz, CDCl3) δ 6.41 (d, J =
2.0 Hz, 1H, 4-H), 6.26 (d, J = 2.0 Hz, 1H, 2-H), 5.75 (s, 1H, OH),
5.42 (m as d, J = 5.0 Hz, 1H, 8-H), 3.66 (s, 3H, −OCH3), 3.22 (dd, J =
15.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.69 (td, J = 11.0 Hz, J = 4.5 Hz, 1H,
10a-H), 2.19−2.10 (m, 1H, 7α-H), 1.86−1.74 (m, 3H, 10β-H, 7β-H,
6a-H), 1.69 (s, 3H, 9-CH3), 1.51 (s, 6H, −C(CH3)2−), 1.38 (s, 3H,
6β-CH3), 1.11 (s, 3H, 6α-CH3).
13C NMR (125 MHz, CDCl3) δ
177.8 (>CO), 155.4 (C-1 or C-5), 155.1 (C-5 or C-1), 144.4, 135.0,
119.4, 111.9, 107.5, 105.4, 77.1 (C-6), 52.6 (−OCH3), 46.3, 44.9, 35.9,
31.7, 28.1, 27.8, 26.5, 26.4, 23.8, 18.8. Mass spectrum (EI) m/z
(relative intensity) 344 (M+, 91), 329 (15), 301 (38), 285 (22), 276
(18), 261 (100), 241 (22), 223 (19). Exact mass (EI) calculated
for C21H28O4 (M
+), 344.1988; found, 344.1992. HPLC (4.6 mm ×
250 mm, Supelco Discovery column, acetonitrile/water) showed
purity 96.5% and retention time 12 min for the title compound.
LC/MS analysis (Waters MicroMass ZQ system) showed purity 96.5%
and retention time 6.6 min for the title compound.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic Acid Ethyl Ester
(8b). The synthesis was carried out as described for 6a using 5b
(300 mg, 0.91 mmol), iodoethane (356 mg, 2.28 mmol), and sodium
bicarbonate (115 mg, 1.37 mmol) in DMF and gave 8b (283 mg, 87%
yield) as a light-yellow gum. IR (neat): 3410, 2959, 2931, 1728, and
1702 (s, >CO), cm−1. 1H NMR (500 MHz, CDCl3) δ 6.41 (d, J =
1.0 Hz, 1H, 4-H), 6.28 (d, J = 1.0 Hz, 1H, 2-H), 5.74 (s, 1H, OH),
5.42 (m as d, J = 5.0 Hz, 1H, 8-H), 4.12 (q,, J = 7.0 Hz, 2H,
−OCH2−), 3.22 (dd, J = 15.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.69 (td,
J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.19−2.10 (m, 1H, 7α-H), 1.88−
1.75 (m, 3H, 10β-H, 7β-H, 6a-H), 1.69 (s, 3H, 9-CH3), 1.50 (s, 6H,
−C(CH3)2−), 1.38 (s, 3H, 6β-CH3), 1.19 (t, J = 7.0 Hz, 3H,
−OCH2CH3), 1.10 (s, 3H, 6α-CH3). Mass spectrum (EI) m/z
(relative intensity) 358 (M+, 92), 343 (17), 315 (39), 285 (48), 275
(100), 241 (35). Exact mass (EI) calculated for C22H30O4 (M
+),
358.2144; found, 358.2145. LC/MS analysis (Waters MicroMass ZQ




ethyl Ester (9a). The synthesis was carried out as described for 6a
using 5b (200 mg, 0.61 mmol), 1,2-dibromoethane (287 mg, 1.53 mmol),
and sodium bicarbonate (77 mg, 0.92 mmol) in DMF and gave 9a
(127 mg, 48% yield) as a light-yellow gum. IR (neat): 3405, 2972,
2918, 1725, and 1701 (s, >CO), 1621, 1577, 1415, 1262 cm−1. 1H
NMR (500 MHz, CDCl3) δ 6.42 (d, J = 1.5 Hz, 1H, 4-H), 6.27 (d, J =
1.5 Hz, 1H, 2-H), 5.42 (m as d, J = 4.0 Hz, 1H, 8-H), 5.04 (br s, 1H,
OH), 4.36 (m as td, J = 5.5 Hz, J = 2.0 Hz, 2H, −OCH2−), 3.46 (t, J =
6.0 Hz, 2H, −CH2Br), 3.19 (dd, J = 15.0 Hz, J = 4.5 Hz, 1H, 10α-H),
2.69 (td, J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.18−2.10 (m, 1H,
7α-H), 1.89−1.72 (m, 3H, 10β-H, 7β-H, 6a-H), 1.70 (s, 3H, 9-CH3),
1.53 (s, 6H, −C(CH3)2−), 1.38 (s, 3H, 6β-CH3), 1.10 (s, 3H, 6α-
CH3). Mass spectrum (EI) m/z (relative intensity) 438 (M
+ + 2, 68),
436 (M+, 68), 395 (22), 393 (22), 355 (67), 353 (67), 285 (44), 241
(45), 59 (100). Exact mass (EI) calculated for C22H29O4Br (M
+),
436.1249; found, 436.1250. LC/MS analysis (Waters MicroMass ZQ




propyl Ester (9b). The synthesis was carried out as described for
6a using 5b (405 mg, 1.23 mmol), 1,3-dibromopropane (622 mg,
3.08 mmol), and sodium bicarbonate (155 mg, 1.85 mmol) in DMF
and gave 9b (282 mg, 51% yield) as a light-yellow gum. IR (neat):
3401, 2973, 2917, 1727, and 1703 (s, >CO), 1621, 1576, 1416,
1260 cm−1. 1H NMR (500 MHz, CDCl3) δ 6.41 (d, J = 1.5 Hz, 1H,
4-H), 6.27 (d, J = 1.5 Hz, 1H, 2-H), 5.89 (s, 1H, OH), 5.42 (m as d,
J = 5.0 Hz, 1H, 8-H), 4.19 (m as td, J = 6.5 Hz, J = 1.5 Hz, 2H,
−OCH2−), 3.30−3.18 (t and dd overlapping, 3H, −CH2Br, 10α-H,
especially 3.24, t, J = 6.5 Hz, 2H, −CH2Br), 2.69 (td, J = 11.0 Hz,
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J = 4.5 Hz, 1H, 10a-H), 2.18−2.10 (m, 1H, 7α-H), 2.09 (qt, J =
6.5 Hz, 2H, −CH2CH2Br), 1.87−1.74 (m, 3H, 10β-H, 7β-H, 6a-H),
1.69 (s, 3H, 9-CH3), 1.51 (s, 6H, −C(CH3)2−), 1.39 (s, 3H, 6β-CH3),
1.11 (s, 3H, 6α-CH3). Mass spectrum (ESI) m/z (relative intensity)
453 (M+ + 2 + H, 55), 450 (M+ + H, 55), 285 (100). LC/MS analysis
(Waters MicroMass ZQ system) showed purity 96% and retention
time 7.6 min for the title compound. Anal. (C23H31BrO4) C, H.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic Acid 5-Bromo-
pentyl Ester (9c). The synthesis was carried out as described for 6a
using 5b (350 mg, 1.06 mmol), 1,5-dibromopentane (609 mg, 2.65 mmol),
and sodium bicarbonate (134 mg, 1.59 mmol) in DMF and gave 9c
(239 mg, 47% yield) as a light-yellow gum. IR (CHCl3): 3408, 2973,
2931, 1728, and 1702 (s, >CO), 1621, 1578, 1417, 1261 cm−1. 1H
NMR (500 MHz, CDCl3) δ 6.42 (d, J = 2.0 Hz, 1H, 4-H), 6.25 (d, J =
2.0 Hz, 1H, 2-H), 5.42 (m as d, J = 5.0 Hz, 1H, 8-H), 5.07 (s, 1H,
OH), 4.03 (t, J = 6.5 Hz, 2H, −OCH2−), 3.29 (t, J = 6.5 Hz, 2H,
−CH2Br), 3.19 (dd, J = 15.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.69 (td, J =
11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.18−2.10 (m, 1H, 7α-H), 1.84−1.67
(m and s overlapping, 10H, 10β-H, 7β-H, 6a-H, −CH2-CH2− of the
side chain and 9-CH3, especially 1.70 s, 9-CH3), 1.51 (s, 6H,
−C(CH3)2−), 1.38 (s, 3H, 6β-CH3), 1.28−1.23 (m, 2H, −CH2− of
the side chain), 1.10 (s, 3H, 6α-CH3). Mass spectrum (EI) m/z
(relative intensity) 480 (M+ + 2, 2), 478 (M+, 2), 398 (M+ − Br, 82),
355 (19), 330 (21), 315 (100), 285 (60), 241 (39). Exact mass (EI)
calculated for C25H35O4Br (M
+), 478.1719; found, 478.1715. LC/MS
analysis (Waters MicroMass ZQ system) showed purity 96% and
retention time 7.5 min for the title compound.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic Acid 4-(1H-Imida-
zol-1-yl)butyl Ester (9d). The synthesis was carried out as described
for 6a using 5b (900 mg, 2.72 mmol), 4-(1H-imidazol-1-yl)butyl bro-
mide (1.12 g, 5.44 mmol), and sodium bicarbonate (343 mg, 4.08 mmol)
in DMF and gave 9d (579 mg, 47% yield) as a light-yellow solid, mp
73−75 °C. IR (CHCl3): 2971, 2932, 1727 (s, >CO), 1618, 1578, 1512,
1417, 1251 cm−1. 1H NMR (500 MHz, CDCl3) δ 7.50 (s, 1H, imidazole),
7.10 (s, 1H, imidazole), 6.86 (s, 1H, imidazole), 6.35 (d, J = 2.0 Hz, 1H,
4-H), 6.23 (d, J = 2.0 Hz, 1H, 2-H), 5.41 (m as d, J = 5.0 Hz, 1H, 8-H),
3.95 (m as td, J = 6.5 Hz, J = 2.0 Hz, 2H, −OCH2−), 3.88 (m as td, J =
7.5 Hz, J = 3.0 Hz, 2H, −CH2−N< ), 3.37 (dd, J = 15.0 Hz, J = 4.5 Hz,
1H, 10α-H), 2.72 (td, J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.18−2.09 (m,
1H, 7α-H), 1.84−1.68 (m and s overlapping, 10H, 10β-H, 7β-H, 6a-H,
−CH2-CH2− of the side chain and 9-CH3, especially 1.70 s, 9-CH3), 1.47
(s, 3H, −C(CH3)2−), 1.46 (s, 3H, −C(CH3)2−), 1.38 (s, 3H, 6β-CH3),
1.09 (s, 3H, 6α-CH3). Mass spectrum (EI) m/z (relative intensity) 452
(M+, 100), 437 (20), 402 (48), 367 (56), 318 (23), 303 (38), 265 (31),
91 (18). Exact mass (EI) calculated for C27H36N2O4 (M
+), 452.2675;
found, 452.2666. Anal. (C27H36N2O4) C, H, N.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]-2-methyl-propanoic Acid 3-Cyano-
propyl Ester (10a). The synthesis was carried out as described for
7a using 9b (110 mg, 0.24 mmol) and sodium cyanide (118 mg,
2.4 mmol) in anhydrous DMSO and gave 10a (95 mg, 98% yield) as
light-yellow gum. IR (CHCl3): 3403, 2971, 2248 (CN), 1727 and
1704 (s, >CO), 1621, 1576, 1421, 1261, 1185 cm−1. 1H NMR
(500 MHz, CDCl3) δ 6.40 (d, J = 2.0 Hz, 1H, 4-H), 6.29 (d, J = 2.0
Hz, 1H, 2-H), 5.82 (s, 1H, OH), 5.42 (m as d, J = 4.0 Hz, 1H, 8-H),
4.17 (m, AB system, 2H, −OCH2−), 3.22 (dd, J = 15.0 Hz, J = 4.5 Hz,
1H, 10α-H), 2.70 (td, J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.21 (t, J =
7.5 Hz, 2H, −CH2CN), 2.18−2.10 (m, 1H, 7α-H), 1.93 (m as qt, J =
6.0 Hz, 2H, −CH2− of the side chain), 1.87−1.75 (m, 3H, 10β-H, 7β-
H, 6a-H), 1.70 (s, 3H, 9-CH3), 1.52 (s, 6H, −C(CH3)2−), 1.38 (s, 3H,
6β-CH3), 1.10 (s, 3H, 6α-CH3). Mass spectrum (EI) m/z (relative
intensity) 397 (M+, 79), 382 (12), 354 (9), 329 (13), 314 (100), 285
(27), 276 (21), 241 (78), 149 (21), 70 (41). Exact mass (EI)
calculated for C24H31NO4 (M
+), 397.2253; found, 397.2254. LC/MS
analysis (Waters MicroMass ZQ system) showed purity 98% and




zol-1-yl)propyl Ester (10b). To a stirred suspension of 9b (196.0 mg,
0.43 mmol) and potassium carbonate (594 mg, 4.30 mmol) in DMSO
(5 mL) was added imidazole (146 mg, 2.15 mmol) at room tem-
perature under an argon atmosphere. Stirring was continued for 14 h,
and then the mixture was diluted with water and ethyl acetate. The
organic layer was separated, and the aqueous layer was extracted with
ethyl acetate. The combined organic layer was washed with water and
brine, dried (MgSO4), and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography on silica gel (50% acetone in hexane) gave
10b (78 mg, 41% yield) as light-yellow gum. IR (CHCl3): 2971, 2932,
1727 (s, >CO), 1618, 1578, 1512, 1417, 1251 cm−1. 1H NMR
(500 MHz, CDCl3) δ 7.33 (s, 1H, imidazole), 7.04 (s, 1H, imidazole),
6.44 (s, 1H, imidazole), 6.40 (d, J = 2.0 Hz, 1H, 4-H), 6.32 (d, J =
2.0 Hz, 1H, 2-H), 5.40 (m as d, J = 5.0 Hz, 1H, 8-H), 3.93 (td, J =
17.0 Hz, J = 5.5 Hz, 1H, −OCH2−), 3.85 (td, J = 17.0 Hz, J = 5.5 Hz,
1H, −OCH2−), 3.72 (t, J = 7.0 Hz, 2H, −CH2−N< ), 3.41 (dd, J =
16.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.73 (td, J = 11.0 Hz, J = 4.5 Hz, 1H,
10a-H), 2.17−2.09 (m, 1H, 7α-H), 2.01−1.93 (m, 2H, −OCH2-
CH2−), 1.85−1.71 (m, 3H, 10β-H, 7β-H, 6a-H), 1.60 (s, 3H, 9-CH3),
1.50 (s, 3H, −C(CH3)2−), 1.49 (s, 3H, −C(CH3)2−), 1.38 (s, 3H, 6β-
CH3), 1.08 (s, 3H, 6α-CH3).
13C NMR (100 MHz, CDCl3) δ 176.8
(>CO), 157.4 (C-1 or C-5), 155.1 (C-5 or C-1), 143.8, 137.5
(imidazole), 135.4, 128.7 (imidazole), 119.4, 119.2, 112.6, 106.0 (C-2
or C-4), 105.7 (C-4 or C-2), 77.0 (C-6), 60.9 (−OCH2−), 46.2, 45.2,
43.8, 36.0, 31.9, 29.8, 28.1, 27.8, 26.1, 25.8, 23.7, 18.7. Mass spectrum
(EI) m/z (relative intensity) 438 (M+, 62), 423 (12), 395 (80, 355 (7),
317 (6), 304 (10), 285 (7), 201 (6), 149 (10, 88 (18), 56 (100). Exact
mass (EI) calculated for C26H34N2O4 (M
+), 438.2519; found, 438.2518.
HPLC (4.6 mm × 250 mm, Supelco discovery column, acetonitrile/
water) showed purity 98% and retention time 7 min for the title
compound. LC/MS analysis (Waters MicroMass ZQ system) showed
purity 98% and retention time 5.5 min for the title compound.
2-(3,5-Dimethoxyphenyl)-2-methylpropanal34 (12). To a solution
of 11 (3.0 g, 14.6 mmol) in dry CH2Cl2 (50 mL) at −78 °C under an
argon atmosphere was added dropwise DIBAL-H (37 mL, 37 mmol,
1 M solution in CH2Cl2). The reaction mixture was stirred at the
same temperature for 1 h and then quenched by dropwise addition of
potassium sodium tartrate (10% solution in water). The resulting
mixture was warmed to room temperature, stirred vigorously for
40 min, and then diluted with ethyl acetate. The organic phase was
separated, and the aqueous phase was extracted with ethyl acetate. The
combined organic layer was washed with brine, dried (MgSO4), and
concentrated under reduced pressure. Puriﬁcation by ﬂash column
chromatography on silica gel (20% ethyl acetate in hexane) gave 12
(2.8 g, 94%) as a colorless oil. IR (neat): 2970, 2937, 1725 (s, >CO),
1592, 1456, 1423, 1204, 1159, 1048 cm−1. 1H NMR (500 MHz, CDCl3)
δ 9.46 (s, −CHO), 6.40 (d, J = 2.0 Hz, 2H, ArH), 6.39 (t, J = 2.0 Hz,
1H, ArH), 3.79 (s, 6H, −OCH3), 1.43 (s, 6H, −C(CH3)2−). Mass
spectrum (EI) m/z (relative intensity) 208 (M+, 25), 196 (16), 179
(M+ − CHO), 165 (25), 151 (14), 139 (39), 91 (20), 77 (20). Exact
mass (EI) calculated for C12H16O3 (M
+), 208.1099; found, 208.1108.
2-(3,5-Dimethoxyphenyl)-2-methylpropan-1-ol (13). To a solution
of 12 (1.70 g, 8.16 mmol) in anhydrous methanol (40 mL) at room
temperature under an argon atmosphere was added sodium
borohydride (1.39 g, 36.7 mmol) portionwise. The reaction mixture
was stirred for 1 h and then quenched by the addition of aqueous 1 N
HCl and extracted with ethyl acetate. The organic layer was washed
with brine, dried (MgSO4), and evaporated. Puriﬁcation by ﬂash
column chromatograph on silica gel (20% ethyl acetate in hexane)
gave 13 (1.6 g, 94%) as a colorless oil. IR (neat): 3433 (br, OH), 2961,
2836, 1592, 1456, 1422, 1202, 1159, 1048 cm−1. 1H NMR (500 MHz,
CDCl3) δ 6.53 (d, J = 2.0 Hz, 2H, ArH), 6.34 (t, J = 2.0 Hz, 1H,
ArH), 3.80 (s, 6H, −OCH3), 3.58 (s, 2H, −CH2OH), 1.30 (s, 6H,
−C(CH3)2−). Mass spectrum (ESI) m/z (relative intensity) 211
(M+ + H, 100).
5-(1-Hydroxy-2-methylpropan-2-yl)resorcinol (14). To a stirred
solution of 13 (400 mg, 1.9 mmol) in dry CH2Cl2 (20 mL) at −78 °C,
under an argon atmosphere, was added boron tribromide (6.6 mL,
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6.6 mmol, 1 M solution in CH2Cl2). Following this addition, the
reaction temperature was gradually raised over a period of 3 h to
25 °C, and the stirring was continued at that temperature until the
reaction was completed (4 h). Unreacted boron tribromide was
destroyed by the addition of methanol and ice at 0 °C. The resulting
mixture was warmed to room temperature, and volatiles were removed
in vacuo. The residue was dissolved in diethyl ether and washed with
water and brine and dried (MgSO4). Solvent evaporation and puriﬁ-
cation by ﬂash column chromatography on silica gel (40% diethyl
ether in hexane) gave 14 (165 mg, 47%) as light-yellow oil. IR (neat):
3443 (br, OH), 2959, 1591, 1458, 1420, 1201, 1048 cm−1. 1H NMR
(500 MHz, CDCl3) δ 6.43 (d, J = 2.0 Hz, 2H, ArH), 6.22 (t, J =
2.0 Hz, 1H, ArH), 4.84 (s, 2H, ArOH), 3.56 (d, J = 6.0 Hz, 2H,
−CH2OH), 1.28 (s, 6H, −C(CH3)2−). Mass spectrum (ESI) m/z
(relative intensity) 183 (M+ + H, 35), 165 (100).
(6aR,10aR)-3-(1-Hydroxy-2-methylpropan-2-yl)-6a,7,10,10a-tet-
rahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol (15). To a stirred
solution of 14 (165 mg, 0.9 mmol) and (+)-cis/trans-p-mentha-2,8-dien-
1-ol (166 mg, 1.09 mmol) in anhydrous CHCl3 (3 mL), under an argon
atmosphere, was added p-toluenesulfonic acid (52 mg, 0.3 mmol). The
reaction mixture was heated at 150 °C for 10 min using microwave
irradiation, and then it was cooled to room temperature and diluted with
water and CHCl3. The organic layer was separated, and the aqueous
phase was extracted with CHCl3. The combined organic layer was
washed with water and brine and dried (MgSO4). Solvent evaporation
and puriﬁcation by ﬂash column chromatography on silica gel (15% ethyl
acetate in hexane) gave 15 (80 mg, 28%) as an orange solid, mp
91−93 °C. IR (CHCl3): 3341 (br, OH), 2968, 1621, 1575, 1415, 1329,
1185 cm−1. 1H NMR (500 MHz, CDCl3) δ 6.42 (d, J = 1.5 Hz, 1H, 4-
H), 6.28 (d, J = 1.5 Hz, 1H, 2-H), 5.43 (m as d, J = 4.5 Hz, 1H, 8-H),
3.54 (s, 2H, −CH2OH), 3.22 (dd, J = 15.5 Hz, J = 4.5 Hz, 1H, 10α-H),
2.70 (td, J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.19−2.11 (m, 1H, 7α-H),
1.90−1.71 (m, 3H, 10β-H, 7β-H, 6a-H), 1.70 (s, 3H, 9-CH3), 1.38 (s,
3H, 6β-CH3), 1.24 (s, 6H, −C(CH3)2−), 1.08 (s, 3H, 6α-CH3). Mass
spectrum (ESI) m/z (relative intensity) 317 (M+ + H, 100). LC/MS
analysis (Waters MicroMass ZQ system) showed purity 97% and
retention time 5.7 min for the title compound.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]- 2-methyl propylpentanoate (16). To a
stirred solution of 15 (180 mg, 0.57 mmol), valeric acid (1.0 mL, 0.8
mmol) and triphenylphosphine (223 mg, 0.85 mmol) in anhydrous
THF (10 mL) at 0 °C, under an argon atmosphere, was added diethyl
azodicarboxylate (0.15 mL, 0.8 mmol) dropwise. The reaction tem-
perature was raised to 25 °C, and stirring was continued for 20 h. The
reaction mixture was quenched with aqueous 1 N HCl solution and
extracted with ethyl acetate. The organic phase was washed with water
and brine and dried (MgSO4). Solvent evaporation and puriﬁcation by
ﬂash column chromatography on silica gel (25% ethyl acetate in
hexane) gave 16 (93 mg, 41%) as light-yellow gum. IR (CHCl3): 3389
(br, OH), 2968, 2891, 1710 (>CO), 1620, 1578, 1417, 1332,
1186 cm−1. 1H NMR (500 MHz, CDCl3) δ 6.42 (d, J = 2.0 Hz, 1H, 4-
H), 6.26 (d, J = 2.0 Hz, 1H, 2-H), 5.43 (m as d, J = 5.0 Hz, 1H, 8-H),
4.94 (s, 1H, OH), 4.05 (s, 2H, −CH2O−), 3.19 (dd, J = 15.5 Hz, J =
5.5 Hz, 1H, 10α-H), 2.69 (td, J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-H),
2.28 (t, J = 7.0 Hz, 2H, −CH2-C(O)−), 2.19−2.11 (m, 1H, 7α-H),
1.89−1.74 (m, 3H, 10β-H, 7β-H, 6a-H), 1.70 (s, 3H, 9-CH3), 1.55 (qt,
J = 7.0 Hz, 2H, −CH2− of the side chain), 1.38 (s, 3H, 6β-CH3),
1.32−1.24 (m and s overlapping, 8H, −C(CH3)2− and −CH2− of the
side chain, especially 1.28, s, −C(CH3)2−), 1.10 (s, 3H, 6α-CH3), 0.88
(t, J = 7.0 Hz, 3H, −CH2−CH3). Mass spectrum (EI) m/z (relative
intensity) 400 (M+, 100), 385 (9), 357 (11), 327 (35), 317 (27), 285
(26), 255 (17), 217 (9). Exact mass (EI) calculated for C25H36O4
(M+), 400.2614; found, 400.2611. Anal. (C25H36O4) C, H.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]- 2-methyl-N-pentylpropanamide (18).
Carboxylic acid intermediate 5b (200 mg, 0.61 mmol) was dissolved in
dry CH2Cl2 (3 mL) under an argon atmosphere and cooled to 0 °C.
To the cold solution, triethylamine (0.12 mL, 0.92 mmol) was added
followed by the dropwise addition of bis(2-methoxyethyl)aminosulfur
triﬂuoride (0.13 mL, 0.72 mmol). After stirring for 15 min, a solution
of amylamine (80 mg, 0.92 mmol) in dry CH2Cl2 (6 mL) was added.
The resulting mixture was stirred at 0 °C for 15 min and at 25 °C for
2 h and then diluted with CH2Cl2 and saturated aqueous sodium
bicarbonate solution. The organic layer was separated, and the aqueous
layer was extracted with ethyl acetate. The combined organic layer was
washed with water and brine, dried (MgSO4), and concentrated in
vacuo. Puriﬁcation by ﬂash column chromatography on silica gel (12%
ethyl acetate in hexane) aﬀorded 18 (170 mg, 70% yield) as light-
yellow gum. IR (neat): 3274, 2930, 1643, and 1618 (>CO), 1577,
1518, 1415, 1264, 1183, 1083 cm−1. 1H NMR (500 MHz, CDCl3) δ
8.53 (s, 1H, >NH), 6.40 (d, J = 1.5 Hz, 1H, 4-H), 6.25 (d, J = 1.5 Hz,
1H, 2-H), 5.46−5.35 (m as d, J = 5.0 Hz, and br s overlapping, 2H,
8-H, OH), 3.41 (dd, J = 16.0 Hz, J = 4.5 Hz, 1H, 10α-H), 3.12 (m as q,
J = 7.0 Hz, 2H, −CH2-N< ), 2.73 (td, J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-
H), 2.20−2.15 (m, 1H, 7α-H), 1.88−1.76 (m, 3H, 10β-H, 7β-H, 6a-
H), 1.70 (s, 3H, 9-CH3), 1.49 (s, 6H, −C(CH3)2−), 1.40 (s, 3H, 6β-
CH3),1.36 (qt, J = 7.0 Hz, 2H, −CH2− of the side chain), 1.18 (qt, J =
7.0 Hz, 2H, −CH2− of the side chain), 1.16−1.08 (m and s
overlapping, 5H, 6α-CH3, −CH2− of the side chain, especially 1.14, s,
6α-CH3), 0.81 (t, J = 7.0 Hz, 3H, −CH2−CH3). Mass spectrum
(EI) m/z (relative intensity) 399 (M+, 25), 286 (100), 220 (21), 205
(82), 164 (15), 149 (18), 88 (23). Exact mass (EI) calculated for
C25H37NO3 (M
+), 399.2773; found, 399.2777. LC/MS analysis
(Waters MicroMass ZQ system) showed purity 96% and retention
time 5.7 min for the title compound.
2-[(6aR,10aR)-6a,7,10,10a-Tetrahydro-1-hydroxy-6,6,9-trimethyl-
6H-dibenzo[b,d]pyran-3-yl]- 2-methyl-propanoyl Chloride (19). To
a stirred solution of acid 5b (90 mg, 0.27 mmol) in dry CH2Cl2
(3.4 mL), at room temperature under an argon atmosphere, was added
the SOCl2−BTA reagent (0.23 mL (0.35 mmol) of a 1.5 M solution in
CH2Cl2, which was prepared by dissolving 0.54 mL (7.5 mmol) of
SOCl2 and 0.893 g (7.5 mmol) of BTA in 5 mL CH2Cl2). Stirring was
continued for 20 min, and insoluble materials were ﬁltered oﬀ. The
ﬁltrate was washed with aqueous 1 N HCl, water, and brine, and then
dried (MgSO4). Solvent evaporation under reduced pressure aﬀorded




(20). To a solution of 19 (95 mg, 0.27 mmol) and propanethiol
(54 mg, 64 μL, 0.71 mmol) in dry CH2Cl2 (5.4 mL) at room tem-
perature, under an argon atmosphere, was added anhydrous pyridine
(0.3 mL). The reaction mixture was stirred for 3 h and then diluted
with water and diethyl ether. The organic layer was separated, and the
aqueous layer was extracted with diethyl ether. The combined organic
layer was washed with water and brine, dried (MgSO4), and con-
centrated in vacuo. Puriﬁcation by ﬂash column chromatography on
silica gel (5−15% diethyl ether in hexane) gave 20 (24 mg, 23% yield
for the two steps) as a pale-yellow gum. IR (CHCl3): 3435, 2966,
2927, 1678, and 1652 (s, >CO), 1620, 1579, 1417, 1264 cm−1. 1H
NMR (500 MHz, CDCl3) δ 6.45 (d, J = 2.0 Hz, 1H, 4-H), 6.24 (d, J =
2.0 Hz, 1H, 2-H), 5.42 (m as d, J = 5.0 Hz, 1H, 8-H), 5.02 (br s, 1H,
OH), 3.19 (dd, J = 16.0 Hz, J = 4.5 Hz, 1H, 10α-H), 2.78 (m as t, J =
7.5 Hz, 1H, −SCH2−), 2.77 (m as t, J = 7.5 Hz, 1H, −SCH2−), 2.70
(td, J = 11.0 Hz, J = 4.5 Hz, 1H, 10a-H), 2.18−2.10 (m, 1H, 7α-H),
1.90−1.74 (m, 3H, 10β-H, 7β-H, 6a-H), 1.70 (s, 3H, 9-CH3), 1.58−
1.50 (m and s overlapping, 8H, −C(CH3)2−, −CH2− of the side
chain, especially 1.54, s, −C(CH3)2−), 1.38 (s, 3H, 6β-CH3), 1.09 (s,
3H, 6α-CH3), 0.92 (t, J = 7.5 Hz, 3H, −CH2-CH3). Mass spectrum
(EI) m/z (relative intensity) 388 (M+, 19), 285 (100). Exact mass (EI)
calculated for C23H32O3S (M
+), 388.2072; found, 388.2075. LC/MS
analysis (Waters MicroMass ZQ system) showed purity 98% and
retention time 7.8 min for the title compound.
Radioligand Binding Assays. Rat brain CB1 receptor, mouse and
human CB2 receptor binding assays: Compounds were tested for their
aﬃnities for the CB1 and CB2 receptors using membrane preparations
from rat brain or HEK293 cells expressing either mCB2 or hCB2
receptors, respectively, and [3H]CP-55,940, as previously described.18,20,32
Results from the competition assays were analyzed using nonlinear
regression to determine the IC50
35 values for the ligand; Ki values were
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calculated from the IC50 (Prism by GraphPad Software, Inc.). Each
experiment was performed in triplicate, and Ki values determined from
three independent experiments and are expressed as the mean of the
three values.
cAMP Assay.16,18 HEK293 cells stably expressing rCB1 receptor
were used for the studies. The cAMP assay was carried out using
PerkinElmer’s Lance ultra cAMP kit following the protocol of the
manufacturer. Brieﬂy, the assays were carried out in 384-well plates
using 1000−1500 cells/well. The cells were harvested with non-
enzymatic cell dissociation reagent Versene and were washed once
with HBSS and resuspended in the stimulation buﬀer. The various
concentrations of the test compound (5 μL) in forskolin (2 μM ﬁnal
concentration) containing stimulation buﬀer were added to the plate
followed by the cell suspension (5 μL). The cells were stimulated for
30 min at room temperature. Then Eu-cAMP tracer working solution
(5 μL) and Ulight-anti-cAMP working solution (5 μL) were added to
the plate and incubated at room temperature for 60 min. The data
were collected on a PerkinElmer Envision instrument. The EC50 values
were determined by nonlinear regression analysis using GraphPad
Prism software (GraphPad Software, Inc., San Diego, CA).
Plasma Stability.16,36 Compounds or their proposed products
were diluted (200 μM) in mouse plasma and incubated at 37 °C,
100 rpm. At various time points, samples were taken, diluted 1:4 in
acetonitrile, and centrifuged to precipitate the proteins. The resulting
supernatant was analyzed by HPLC. In vitro plasma half-lives were
determined using exponential decay calculations in Prism (GraphPad).
HPLC Analysis. Chromatographic separation was achieved using a
Supelco Discovery C18 (4.6 mm × 250 mm) column on a Waters
Alliance HPLC system. Mobile phase consisted of acetonitrile (A) and
a mixture of 60% water (acidiﬁed with 8.5% o-phosphoric acid) and
40% acetonitrile (B). Gradient elution started with 5% A, transitioning
to 95% A over 10 min and holding for 5 min before returning to
starting conditions; run time was 15 min, the ﬂow rate was 1 mL/min,
and UV detection was used at each compound’s maximal absorbance
(204 and 230 nM).
Molecular Modeling. Ballesteros−Weinstein Nomenclature.
The Ballesteros−Weinstein numbering system for GPCR amino acid
residues is used here.37 In this numbering system, the label 0.50 is
assigned to the most highly conserved class A residue in each trans-
membrane helix (TMH). This is preceded by the TMH number. In
this system, for example, the most highly conserved residue in TMH6
is P6.50. The residue immediately before this would be labeled 6.49,
and the residue immediately after this would be labeled 6.51. When
referring to a speciﬁc CB1 residue, the Ballesteros−Weinstein name is
followed by the absolute sequence number given in parentheses (e.g.,
K3.28(192)); however, when referring to a highly conserved residue
among class A GPCRs (and not a speciﬁc residue in CB1), only the
Ballesteros−Weinstein name is given.
Conformational Searches. The structures of the ligands (−)-Δ8-
THC, (−)-Δ8-THC-dimethylheptyl, and 10a were built in Spartan’08
(Wave function, Inc., Irvine, CA). Initial conformational analyses of
these compounds were performed in vacuo using the semiempirical
method RM1 encoded in Spartan’08. Conformational searches were
performed (using 3−8-fold rotations) for each rotatable bond. All
unique conformers identiﬁed were then optimized with ab initio
Hartree−Fock calculations at the 6-31G* level. To calculate the
diﬀerence in energy between the global minimum energy conformer of
each compound and its ﬁnal docked conformation, rotatable bonds in
the global minimum energy conformer were driven to their corre-
sponding value in the ﬁnal docked conformation and the single-point
energy of the resultant structure was calculated at the HF 6-31G*.
A duplicate conformational search of 10a was conducted at high
dielectric using the MCMM (Monte Carlo multiple minimum) pro-
tocol in MacroModel with the OPLS_2005 force ﬁeld in a GB/SA
water model with an extended cutoﬀ.38,39 An energy window of
21.0 kJ/mol (5 kcal/mol) was employed, and the redundant conformers
of 10a were eliminated using a rmsd cutoﬀ of 0.5 Å for all atoms.
CB1R Active State Model. The studies reported here used our
previously published CB1 activated state model.40 Below, we describe
brieﬂy the construction of both the inactive and active states of this
model. Because no crystal structure of the CB1 receptor has been
published, the CB1 model uses the crystal structure of the class A
GPCR rhodopsin in the dark state as its template.41 This template was
chosen because no mutations or modiﬁcations were made to its
structure for crystallization and because the cannabinoid receptors and
rhodopsin share some unusual sequence motifs that have important
spatial relevance. For example, these receptors share a TMH4 GWNC
motif at their extracellular ends. Here a TRP forms an aromatic stack-
ing interaction with Y5.39, inﬂuencing the extracellular (EC) positions
of TMH3−4−5. Changes to the general Rho structure that were
necessitated by sequence divergences included the absence of helix
kinking proline residues in TMH1 and TMH5, the lack of a GG motif
in TMH2 (at position 2.56 and 2.57), as well as the presence of extra
ﬂexibility in the TMH6 CWXP motif because of the presence of G6.49
immediately before P6.50.42 An activated state (R*) CB1 model was
created by modiﬁcation of our inactive state model. This R* model
construction was guided by the biophysical literature on the R-to-R*
transition in rhodopsin (Rho) and included a TMH6 conformer
derived from our Conformational Memories study of CB1 TMH6 that
is straightened, breaking the ionic lock interaction between R3.50 and
D6.30.43 Extracellular (EC-1, H181−S185; EC-2, C257−E273; EC-3,
D366−K376) and intracellular (IC-1, S146−R150; IC-2, P221−V228;
IC-3, A301−P332) loops, as well as portions of the N (K90−N112)
and C termini (S414−G427), were then added to the reﬁned model of
the CB1 R* bundle. The Modeler program was then used to reﬁne
loop structures.44,45 Speciﬁc conformations of the EC-2 and EC-3 loop
were reﬁned to reﬂect mutagenesis data showing that EC-2 loop
residue F(268) should be available to the binding crevice and that
EC-3 loop residue K(373) should interact in a salt bridge with TMH2
residue D2.63(176).46,47
Ligand/CB1R* Complexes. The automatic docking program, Glide
v6.4 (Schrödinger, LLC, NY 2014) was used to explore possible bind-
ing conformations or receptor site interactions for subject ligands.
Because K3.28(192) has been shown to be a critical residue for
classical cannabinoid binding,48 K3.28(192) was deﬁned as a required
interaction during the docking procedure. Glide was used to generate a
grid based on the centroid of the ligand in the binding site. Any
hydrophobic region deﬁned in the grid generation that contacted the
ligand was selected as important to the docking procedure. The box
for Glide docking was deﬁned to be 22 Å in the x, y, and z dimensions.
The lowest energy conformations (<4 kcal/mol above the global min)
of each ligand were docked using Glide. Extra precision (XP) was
selected with no scaling of VdW radii and rigid docking invoked. Glide
scoring functions do not take into account the conformational cost, or
internal strain energy, of each generated pose of a ligand inside the
binding pocket of the receptor. To determine the best ligand/receptor
complex to proceed with a postdocking minimization for the acqui-
sition of pairwise interaction energies, the conformational cost for each
pose was subtracted from the Glide score for all poses (Supporting
Information, Tables S2−4). The pose with the ﬁnal best score was
then subjected to a post docking minimization in two stages using the
OPLS2005 all atom force ﬁeld in Macromodel 10.5 (Schrödinger,
LLC, NY 2014). An 8.0 Å nonbonded cutoﬀ (updated every 10 steps),
a 20.0 Å electrostatic cutoﬀ, and a 4.0 Å hydrogen bond cutoﬀ were
used in each stage of the calculation. The ﬁrst stage consisted of
Polak−Ribier conjugate gradient minimization using a distance-
dependent dielectric function with a base constant of 2. No harmonic
constraints were placed on the side chains, but 1000 kJ/mol ﬁxed atom
constraints were applied to hold all the backbone atoms in place. The
termini and loops were not allowed to move during this part of the
procedure. The minimization was continued until the bundle reached
the 0.05 kJ/mol·A2 gradient. To relax the loops, a second stage Polak−
Ribier conjugate gradient minimization of the loop regions was
performed until the 0.05 kJ/mol·A2 gradient was reached. The loop
and termini regions were left free, while the transmembrane regions
and ligand were not allowed to move during this ﬁnal stage. An 8.0 Å
extended nonbonded cutoﬀ (updated every 10 steps), 20.0 Å
electrostatic cutoﬀ, and 4.0 Å hydrogen bond cutoﬀ were used in
this calculation, and the generalized Born/surface area (GB/SA)
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continuum solvation model for water available in Macromodel was
employed.
Assessment of Pairwise Interaction and Total Energies.
Interaction energies between each bound ligand and residue in the
CB1R* complex were calculated using Macromodel, as described
previously.49 Speciﬁcally, after deﬁning the atoms of the ligand as one
group (group 1) and the atoms corresponding to a residue that lines
the binding site in the ﬁnal ligand-CB1R* complex as another group
(group 2), Macromodel was used to output the pairwise interaction
energy (Coulombic and van der Waals) for a given pair.
Methods for Characterization of in Vivo Eﬀects.18,50 Subjects.
For hypothermia testing, female Sprague−Dawley rats (n = 6/group),
weighing between 250 and 350 g (Charles River, Wilmington MA)
were used. Rats were tested repeatedly with at least 5 days intervening
between drug sessions. Experiments occurred at approximately the
same time (10:00 a.m.−5:00 p.m.) during the light portion of the daily
light/dark cycle. Outside of experimental sessions, rats were pair
housed (2/cage) in a climate controlled vivarium with unrestricted
access to food and water. For tail-ﬂick withdrawal (analgesia) testing,
male CD-1 mice (n = 6/group), weighing between 30 and 35 g
(Charles River, Wilmington MA), were used. Mice were housed
4/cage in a climate controlled vivarium with unrestricted access to
food and water and acclimated to these conditions for at least a week
before any experimental manipulations occurred. Analgesia testing
took place between 11:00 a.m. and 7:00 p.m. Mice were used once.
Procedures. Temperature was recorded using a thermistor probe
(Model 401, Measurement Specialties, Inc., Dayton, OH) inserted to a
depth of 6 cm and secured to the tail with micropore tape. Rats were
minimally restrained and isolated in 38 × 50 × 10 cm3 plastic stalls.
Temperature was read to the nearest 0.01 °C using a thermometer
(model 4000A, Measurement Specialties, Inc.).
Two baseline temperature measures were recorded at 15 min
intervals, and drugs were injected immediately after the second
baseline was recorded. After injection, temperature was recorded every
30 min for 3 h and every hour thereafter for a total of 6 h. In some
studies, temperature readings at later time points were obtained by
inserting the probe 6 cm and holding it in place for at least 1 min
before taking a reading. The change in temperature was determined
for each rat by subtracting temperature readings from the average of
the two baseline measures. Analgesia testing utilized a thermostatically
controlled 2 L water bath commercially available from VWR Inter-
national where the water temperature was set at 52 °C (±0.5 °C). The
tail was immersed into the water at a depth of 2 cm and the withdrawal
latency recorded by a commercially available stopwatch (Fisher
Scientiﬁc), allowing measurements in seconds and 1/100 s. Cut-oﬀ
was set at 10 s to minimize the risk of tissue damage. A test session
consisted of ﬁve recordings, the ﬁrst of which constituted the baseline
recording. Injections occurred immediately after the baseline record-
ing, and the remaining recordings took place 20, 60, 180, and 360 min
post administration. Prior to this testing, the animals had been
accustomed to the procedure for three consecutive “mock” sessions
where the water was held at 38 °C, i.e., average body temperature of
mice; no tail-ﬂicks were elicited by this water temperature. The third
“mock” session also included an ip injection of vehicle (10 mL/kg).
The tail-ﬂick withdrawal latencies are expressed as a percentage of
maximum possible eﬀect (%MPE), according to the formula: %MPE =
[(test latency − baseline latency)/(10 − baseline latency)] × 100.
Drugs. For hypothermia testing, (−)-Δ8-THC-DMH and com-
pounds 2b and 10a were initially dissolved in a solution of 20%
ethanol, 20% alkamuls, and 60% saline and were further diluted with
saline. Injections were administered sc in a volume of 1.0 mL/kg. For
tail-ﬂick withdrawal (analgesia) testing, 10a and 2b were initially
dissolved in 2% dimethyl sulfoxide, 4% Tween-80, and 4% propylene
glycol before saline was slowly added just prior to the 10 mL/kg ip
administration. All suspensions were freshly prepared for analgesia
testing.
Data Analysis. Time-eﬀect functions for hypothermia testing were
analyzed using two-way repeated measures ANOVA procedures
followed by Bonferroni’s posthoc test. Hypothermia dose−eﬀect func-
tions for compounds (−)-Δ8-THC-DMH, 2b, and 10a were analyzed
using one-way repeated measures ANOVA procedures followed by
the Holm−Sidak multiple comparisont-test; p was set at ≤0.05, and
statistical analyses were performed using the software package
GraphPad Prism 5.03 (GraphPad Software, San Diego, CA). A linear
mixed model repeated measures ANOVA (IBM software package
SPSS, v.21) was applied to tail-ﬂick latency data depicted in Figure 5.
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